

ANO7 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP9421a**Specification**

ANO7 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q6IWH7](#)**ANO7 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 50636**Other Names**

Anoctamin-7, Dresden transmembrane protein of the prostate, D-TMPP, IPCA-5, New gene expressed in prostate, Prostate cancer-associated protein 5, Transmembrane protein 16G, ANO7, NGEP, PCANAP5, TMEM16G

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ANO7 Antibody (N-term) Blocking Peptide - Protein Information**Name** ANO7**Synonyms** NGEP, PCANAP5, TMEM16G**Function**

Has calcium-dependent phospholipid scramblase activity; scrambles phosphatidylserine, phosphatidylcholine and galactosylceramide (By similarity). Does not exhibit calcium-activated chloride channel (CaCC) activity (PubMed:22075693). May play a role in cell-cell interactions (PubMed:17308099).

Cellular Location

[Isoform 1]: Cell membrane; Multi-pass membrane protein. Cell junction. Endoplasmic reticulum. Note=Concentrates at sites of cell-cell contact (PubMed:17308099). Shows an intracellular localization according to PubMed:22075693 and PubMed:20056604

Tissue Location

Specifically expressed in epithelial cells of the prostate (at protein level).

ANO7 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

ANO7 Antibody (N-term) Blocking Peptide - Images**ANO7 Antibody (N-term) Blocking Peptide - Background**

ANO7 may act as a calcium-activated chloride channel. This protein May play a role in cell-cell interactions.

ANO7 Antibody (N-term) Blocking Peptide - References

Cereda, V., et al. Cancer Immunol. Immunother. 59(1):63-71(2010)Hartzell, H.C., et al. J. Physiol. (Lond.) 587 (PT 10), 2127-2139 (2009) Das, S., et al. Cancer Res. 68(15):6306-6312(2008)Kiessling, A., et al. Prostate 64(4):387-400(2005)Katoh, M., et al. Int. J. Mol. Med. 14(4):759-764(2004)